These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34300332)

  • 41. The coronary resorbable magnesium scaffold Magmaris®: what we have learnt (so far…).
    Bennett J; McCUTCHEON K
    Minerva Cardiol Angiol; 2021 Apr; 69(2):215-221. PubMed ID: 32326679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 12-month clinical outcomes after Magmaris percutaneous coronary intervention in a real-world cohort of patients: Results from the CardioHULA registry.
    Abellas-Sequeiros RA; Ocaranza-Sanchez R; Bayon-Lorenzo J; Santas-Alvarez M; Gonzalez-Juanatey C
    Rev Port Cardiol (Engl Ed); 2020 Aug; 39(8):421-425. PubMed ID: 32763098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
    Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
    Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
    Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
    Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanical behavior of polymer-based
    Ang HY; Huang YY; Lim ST; Wong P; Joner M; Foin N
    J Thorac Dis; 2017 Aug; 9(Suppl 9):S923-S934. PubMed ID: 28894598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiographically Based Direct Implantation of the Bioresorbable Vascular Scaffold in Non-ST Segment Elevation Acute Coronary Syndrome: Feasibility and Outcome.
    Nour MK; Fathelbab HT; Mwafy AH; Shawky MA; Freire SJC; Jiménez JL; Garrido JR; Menchero AEG; Piris RC; Fernández JFD; Tawfik SE
    Open Access Maced J Med Sci; 2019 Aug; 7(15):2419-2423. PubMed ID: 31666839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST elevation myocardial infarction.
    Zhang Q; Shen J; Zhang RY; Qiu JP; Lu JD; Zhang Y; Chen YH; Zhang JF; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Chin Med J (Engl); 2007 Nov; 120(21):1862-7. PubMed ID: 18067756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population.
    Wiebe J; Gilbert F; Dörr O; Liebetrau C; Wilkens E; Bauer T; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):975-81. PubMed ID: 26269391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.
    Anadol R; Schnitzler K; Lorenz L; Weissner M; Ullrich H; Polimeni A; Münzel T; Gori T
    BMC Cardiovasc Disord; 2018 May; 18(1):92. PubMed ID: 29743023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Magmaris very late in-scaffold restenosis: Has the "black boxes" nightmare come back?
    Bayón J; Santás-Álvarez M; Ocaranza-Sánchez R; González-Juanatey C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E174-E176. PubMed ID: 31763757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of bioresorbable vascular scaffolds in acute coronary syndrome: A two-center, one-year follow-up analysis.
    Iwańczyk S; Hiczkiewicz J; Araszkiewicz A; Łanocha M; Adamczak D; Faron W; Grajek S; Lesiak M
    Cardiol J; 2018; 25(4):479-486. PubMed ID: 29168541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
    Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical impact of diabetes mellitus on 2-year clinical outcomes following PCI with second-generation drug-eluting stents; Landmark analysis findings from patient registry: Pooled analysis of the Korean multicenter drug-eluting stent registry.
    Lee CH; Choi SW; Jun SW; Hwang J; Kim IC; Cho YK; Park HS; Yoon HJ; Kim H; Nam CW; Han S; Kim KB; Hur SH
    PLoS One; 2020; 15(6):e0234362. PubMed ID: 32520973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.